CMPX Compass Therapeutics, Inc.
$0.75▲ +0.03%
Healthcare
Other
After hours
$0.75▼ -0.19%
Oct 27, 5:56 PM ET
Volume 2.21M
Avg Volume (10D) 2.72M
Key Metrics & Fundamentals
Market Cap
$134.60M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.73 - 6.88
% vs 50 MA
-52.12%
% vs 200 MA
-77.10%
RSI-14
21.1
MACD Histogram
+0.0300
Beta (1Y vs SPY)
1.42
Free Cash Flow
-$14.91M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$26.60M
COGS
–
Operating Exp
$26.98M
Operating Income
-$26.98M
EBIT
-$26.98M
Pretax Income
-$25.15M
Net Income
-$25.15M
EPS (Diluted)
-0.13
Price & Volume History
Loading chart…
Recent News
Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026
GlobeNewswire · Oct 24, 2026 4:15 AM ET
Emergent BioSolutions stock falls as CFO plans retirement
Investing.com · Oct 16, 2026 11:41 AM ET
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Oct 14, 2026 4:30 PM ET
Compass Therapeutics (CMPX) Stock Fair Value Falls After Tovecimig Regulatory Concerns
Simply Wall St. · Oct 13, 2026 10:13 PM ET
Sector Update: Healthcare Stocks Decline Late Afternoon
MT Newswires · Sep 23, 2026 3:49 PM ET
Sector Update: Healthcare
MT Newswires · Sep 23, 2026 3:18 PM ET
Compass Therapeutics Shares Drop After Downgrade From Wedbush
MT Newswires · Sep 23, 2026 2:18 PM ET
Compass Therapeutics’ FDA Setback Raises Concerns On Wall Street — H.C. Wainwright Calls Tovecimig Filing Strategy ‘Risky’
Stocktwits · Sep 23, 2026 9:44 AM ET
Wedbush Downgrades Compass Therapeutics to Neutral From Outperform, Cuts Price Target to $1 From $5
MT Newswires · Sep 23, 2026 6:15 AM ET
CMPX Plunge Wipes Out $104M After FDA Demands Fresh Trial For Cancer Drug — Wedbush Sees Another 19% Downside
Stocktwits · Sep 22, 2026 7:07 PM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See CMPX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.